Trutino Biosciences

Executive Summary

Trutino Biosciences is a preclinical-stage biotechnology company developing conditionally activated cytokine therapies (ODCs) designed to restore immune balance by targeting the disease site while minimizing systemic toxicity. Founded in 2018 and headquartered in San Diego, the company's platform engineers cytokines for optimal retention and localized activation, enabling safe stimulation of cancer-fighting immune cells. This approach aims to overcome the dose-limiting toxicities and poor tumor penetration that have historically hampered cytokine-based immunotherapies. Trutino's lead programs focus on oncology, leveraging proprietary protein engineering to achieve tumor-selective activity. As a private, early-stage company, Trutino has not disclosed funding details nor clinical timelines, but its novel delivery mechanism positions it within the competitive landscape of next-generation cytokine therapies. The company's progress depends on advancing preclinical candidates to IND-enabling studies and generating robust in vivo proof-of-concept data.

Upcoming Catalysts (preview)

• Q1 2027IND-enabling studies initiation for lead ODC candidate70% success
• Q2 2026Preclinical efficacy data presentation at major oncology conference60% success
• Q4 2026Series A or seed extension financing announcement50% success